Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Aug 30;120(9):1888-98. doi: 10.1182/blood-2011-09-380808. Epub 2012 Jul 26.

2.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.

3.

Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.

Gorantla SP, Dechow TN, Grundler R, Illert AL, Zum Büschenfelde CM, Kremer M, Peschel C, Duyster J.

Blood. 2010 Nov 25;116(22):4600-11. doi: 10.1182/blood-2009-07-236133. Epub 2010 Aug 9.

4.

STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.

Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T.

J Biol Chem. 2010 Feb 19;285(8):5296-307. doi: 10.1074/jbc.M109.040733. Epub 2009 Dec 22.

5.

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Gery S, Cao Q, Gueller S, Xing H, Tefferi A, Koeffler HP.

J Leukoc Biol. 2009 Jun;85(6):957-65. doi: 10.1189/jlb.0908575. Epub 2009 Mar 17.

6.

Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.

Pecquet C, Staerk J, Chaligné R, Goss V, Lee KA, Zhang X, Rush J, Van Hees J, Poirel HA, Scheiff JM, Vainchenker W, Giraudier S, Polakiewicz RD, Constantinescu SN.

Blood. 2010 Feb 4;115(5):1037-48. doi: 10.1182/blood-2008-10-183558. Epub 2009 Dec 8.

7.

Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.

Lu X, Huang LJ, Lodish HF.

J Biol Chem. 2008 Feb 29;283(9):5258-66. Epub 2007 Dec 23.

8.

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL.

PLoS Med. 2006 Jul;3(7):e270.

9.

Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schenkein DP, Gilliland DG.

Blood. 2006 Aug 15;108(4):1339-45. Epub 2006 Apr 20.

10.

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.

Lu X, Levine R, Tong W, Wernig G, Pikman Y, Zarnegar S, Gilliland DG, Lodish H.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18962-7. Epub 2005 Dec 19.

11.

Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.

Rubert J, Qian Z, Andraos R, Guthy DA, Radimerski T.

BMC Cancer. 2011 Jan 19;11:24. doi: 10.1186/1471-2407-11-24.

12.

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.

Mercher T, Wernig G, Moore SA, Levine RL, Gu TL, Fröhling S, Cullen D, Polakiewicz RD, Bernard OA, Boggon TJ, Lee BH, Gilliland DG.

Blood. 2006 Oct 15;108(8):2770-9. Epub 2006 Jun 27.

13.

The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V.

Noël LA, Arts FA, Montano-Almendras CP, Cox L, Gielen O, Toffalini F, Marbehant CY, Cools J, Demoulin JB.

Mol Oncol. 2014 May;8(3):728-40. doi: 10.1016/j.molonc.2014.02.003. Epub 2014 Feb 17.

14.

SOCS2: inhibitor of JAK2V617F-mediated signal transduction.

Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Röhrs S, Romani J, Scherr M, Zaborski M, Drexler HG.

Leukemia. 2008 Dec;22(12):2169-75. doi: 10.1038/leu.2008.226. Epub 2008 Sep 4.

PMID:
18769447
15.

Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.

Tong W, Zhang J, Lodish HF.

Blood. 2005 Jun 15;105(12):4604-12. Epub 2005 Feb 10.

16.

JAK2 and MPL mutations in myeloproliferative neoplasms.

Koppikar P, Levine RL.

Acta Haematol. 2008;119(4):218-25. doi: 10.1159/000140634. Epub 2008 Jun 20. Review.

PMID:
18566540
17.

Critical requirement for Stat5 in a mouse model of polycythemia vera.

Yan D, Hutchison RE, Mohi G.

Blood. 2012 Apr 12;119(15):3539-49. doi: 10.1182/blood-2011-03-345215. Epub 2011 Dec 5.

18.

Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.

Kamishimoto J, Tago K, Kasahara T, Funakoshi-Tago M.

Cell Signal. 2011 May;23(5):849-56. doi: 10.1016/j.cellsig.2011.01.009. Epub 2011 Jan 19.

PMID:
21255641
19.

Hypoxia inhibits JAK2V617F activation via suppression of SHP-2 function in myeloproliferative neoplasm cells.

Mitsumori T, Nozaki Y, Kawashima I, Yamamoto T, Shobu Y, Nakajima K, Morishita S, Komatsu N, Kirito K.

Exp Hematol. 2014 Sep;42(9):783-92.e1. doi: 10.1016/j.exphem.2014.05.007. Epub 2014 May 23.

PMID:
24860972
20.

Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.

Funakoshi-Tago M, Sumi K, Kasahara T, Tago K.

PLoS One. 2013;8(1):e52844. doi: 10.1371/journal.pone.0052844. Epub 2013 Jan 3.

Items per page

Supplemental Content

Write to the Help Desk